Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Medicine (Baltimore) ; 102(47): e36122, 2023 Nov 24.
Artigo em Inglês | MEDLINE | ID: mdl-38013289

RESUMO

BACKGROUND: We compared the efficacy and safety of low-intensity atorvastatin and ezetimibe combination therapy with moderate-intensity atorvastatin monotherapy in patients requiring cholesterol-lowering therapy. METHODS: At 19 centers in Korea, 290 patients were randomized to 4 groups: atorvastatin 5 mg and ezetimibe 10 mg (A5E), ezetimibe 10 mg (E), atorvastatin 5 mg (A5), and atorvastatin 10 mg (A10). Clinical and laboratory examinations were performed at baseline, and at 4-week and 8-week follow-ups. The primary endpoint was percentage change from baseline in low-density lipoprotein (LDL) cholesterol levels at the 8-week follow-up. Secondary endpoints included percentage changes from baseline in additional lipid parameters. RESULTS: Baseline characteristics were similar among the study groups. At the 8-week follow-up, percentage changes in LDL cholesterol levels were significantly greater in the A5E group (49.2%) than in the E (18.7%), A5 (27.9%), and A10 (36.4%) groups. Similar findings were observed regarding the percentage changes in total cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B levels. Triglyceride levels were also significantly decreased in the A5E group than in the E group, whereas high-density lipoprotein levels substantially increased in the A5E group than in the E group. In patients with low- and intermediate-cardiovascular risk, 93.3% achieved the target LDL cholesterol levels in the A5E group, 40.0% in the E group, 66.7% in the A5 group, and 92.9% in the A10 group. In addition, 31.4% of patients in the A5E group, 8.1% in E, 9.7% in A5, and 7.3% in the A10 group reached the target levels of both LDL cholesterol < 70 mg/dL and reduction of LDL ≥ 50% from baseline. CONCLUSIONS: The addition of ezetimibe to low-intensity atorvastatin had a greater effect on lowering LDL cholesterol than moderate-intensity atorvastatin alone, offering an effective treatment option for cholesterol management, especially in patients with low and intermediate risks.


Assuntos
Anticolesterolemiantes , Azetidinas , Ácidos Heptanoicos , Inibidores de Hidroximetilglutaril-CoA Redutases , Hipercolesterolemia , Humanos , Atorvastatina/uso terapêutico , Anticolesterolemiantes/uso terapêutico , LDL-Colesterol , Hipercolesterolemia/tratamento farmacológico , Azetidinas/uso terapêutico , Ácidos Heptanoicos/efeitos adversos , Pirróis/uso terapêutico , Quimioterapia Combinada , Ezetimiba/uso terapêutico , Colesterol , Resultado do Tratamento , Método Duplo-Cego , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico
2.
Korean Circ J ; 42(8): 565-7, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22977454

RESUMO

An isolated single coronary artery is rare but often associated with other congenital cardiac malformations and myocardial ischemia. We report a rare case of right ventricular myocardial infarction due to total occlusion of the right coronary artery originating from the distal left circumflex artery.

4.
Yonsei Med J ; 51(5): 676-82, 2010 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-20635441

RESUMO

PURPOSE: Metabolic syndrome (MS) has been reported as a potential risk factor of coronary artery disease (CAD). The aims of this study were to assess whether there was a relationship between MS score and CAD angiographic severity, and to assess the predictive value of individual components of MS for CAD. MATERIALS AND METHODS: We retrospectively enrolled 632 patients who underwent coronary angiography for suspected CAD (394 men, 61.0 +/- 10.6 years of age). MS was defined by the National Cholesterol Education Program criteria with the waist criterion modified into a body mass index (BMI) of more than 25 kg/m(2). The MS score defined as the number of MS components. CAD was defined as > 50% luminal diameter stenosis of at least one major epicardial coronary artery. CAD angiographic severity was evaluated with a Gensini scoring system. RESULTS: Of the patients, 497 (78.6%) had CAD and 283 (44.8%) were diagnosed with MS. The MS score was significantly related to the Gensini score. High fasting blood glucose (FBG) was the only predictive factor for CAD. A cluster including high FBG, high blood pressure (BP), and low high-density lipoprotein cholesterol (HDL-C) showed the highest CAD risk. CONCLUSION: The MS score correlates with the angiographic severity of CAD. The predictive ability of MS for CAD was carried almost completely by high FBG, and individual traits with high BP and low HDLC may act synergistically as risk factors for CAD.


Assuntos
Angiografia Coronária , Doença da Artéria Coronariana/complicações , Síndrome Metabólica/complicações , Idoso , Doença da Artéria Coronariana/diagnóstico por imagem , Doença da Artéria Coronariana/etiologia , Feminino , Humanos , Masculino , Síndrome Metabólica/diagnóstico por imagem , Pessoa de Meia-Idade , Estudos Retrospectivos , Fatores de Risco , Índice de Gravidade de Doença
5.
Angiology ; 59(6): 676-81, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18388053

RESUMO

The beneficial effect of beta-blockers is reported in myocardial infarction (MI). This study compared the effects of propranolol and carvedilol on left-ventricular (LV) volume and function after acute MI. Serial echocardiographic studies were performed on acute MI patients who were treated with primary coronary stenting and medical treatment, including propranolol or carvedilol. Determinants of the changes in LV volume and function were identified by regression analyses. At 6 months, there was no significant difference in change in the LV end-diastolic volume between patients receiving 2 beta-blockers. The increase of LV ejection fraction was greater in patients receiving carvedilol. On multivariate analyses, it was found that the kind of beta-blocker had no significant influence on the changes in LV volume or ejection fraction, whereas gender and baseline LV ejection fraction were predictive of change in LV ejection fraction. Compared with propranolol, carvedilol did not have a significant benefit on LV remodeling or function after primary coronary stenting in acute MI.


Assuntos
Antagonistas Adrenérgicos beta/uso terapêutico , Angioplastia Coronária com Balão/instrumentação , Carbazóis/uso terapêutico , Ventrículos do Coração/efeitos dos fármacos , Infarto do Miocárdio/terapia , Propanolaminas/uso terapêutico , Propranolol/uso terapêutico , Stents , Função Ventricular Esquerda/efeitos dos fármacos , Idoso , Pressão Sanguínea/efeitos dos fármacos , Carvedilol , Feminino , Frequência Cardíaca/efeitos dos fármacos , Ventrículos do Coração/diagnóstico por imagem , Ventrículos do Coração/fisiopatologia , Humanos , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio/tratamento farmacológico , Infarto do Miocárdio/fisiopatologia , Estudos Retrospectivos , Volume Sistólico/efeitos dos fármacos , Fatores de Tempo , Resultado do Tratamento , Ultrassonografia
6.
Korean J Intern Med ; 22(4): 296-9, 2007 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18309692

RESUMO

Primary duodenal mucosa associated lymphoid tissue (MALT) lymphoma is very rare, and little is known about its clinical course or effective treatment. We describe a case of primary duodenal MALT lymphoma that was resistant to Helicobacter pylon (H. pylori) eradication and regressed after chemotherapy with cyclophosphamide, vincristine, and prednisolone (CVP). A 71-year-old woman was referred to our department because of epigastric pain and dyspepsia. Gastroduodenoscopy revealed an irregular mucosal nodular lesion with ulceration extending from the bulb to the second portion of the duodenum. Histopathological examination of a biopsy specimen disclosed low-grade MALT lymphoma composed of atypical lymphoid cells with lymphoepithelial lesion. Abdominal CT scans revealed 0.5 to 1.5 cm lymph nodes in the peritoneal cavity, suggestive of lymph node metastasis. We successfully eradicated H. pylori but did not see signs of remission. We administered systemic CVP chemotherapy every 3 weeks. After 6 courses of CVP, the patient achieved complete remission and was followed up without recurrence for about a year.


Assuntos
Duodeno/patologia , Linfoma de Zona Marginal Tipo Células B/patologia , Idoso , Protocolos Antineoplásicos , Ciclofosfamida , Feminino , Infecções por Helicobacter , Humanos , Linfoma de Zona Marginal Tipo Células B/diagnóstico , Prednisolona , Vincristina
7.
Clin Cardiol ; 29(9): 418-20, 2006 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-17007175

RESUMO

In some patients with acute myocardial infarction (MI), wall motion in the noninfarcted area declines globally despite localized myocardial damage. In most, an infarct-related lesion is the proximal part of the left anterior descending artery (LAD). Previous studies have reported that hypokinesis of remote myocardium may be related to multivessel disease, impaired coronary flow, or coronary flow reserve in nonculprit arteries. This report describes the case of a 53-year-old man who presented with severe global left ventricular (LV) dysfunction after an acute MI associated with distal LAD occlusion. Follow-up echocardiographic examination revealed nearly normalized LV function 5 days after the episode. We discuss a plausible mechanism of dysfunction of noninfarcted myocardium.


Assuntos
Estenose Coronária/complicações , Estenose Coronária/fisiopatologia , Infarto do Miocárdio/complicações , Infarto do Miocárdio/fisiopatologia , Disfunção Ventricular Esquerda/etiologia , Disfunção Ventricular Esquerda/fisiopatologia , Angioplastia Coronária com Balão , Velocidade do Fluxo Sanguíneo , Angiografia Coronária , Circulação Coronária , Estenose Coronária/diagnóstico , Estenose Coronária/terapia , Ecocardiografia , Humanos , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio/diagnóstico , Infarto do Miocárdio/terapia , Volume Sistólico , Disfunção Ventricular Esquerda/diagnóstico , Disfunção Ventricular Esquerda/terapia
8.
Coron Artery Dis ; 17(3): 249-53, 2006 May.
Artigo em Inglês | MEDLINE | ID: mdl-16728875

RESUMO

OBJECTIVES: Although cardiac troponin I is widely used as a marker for myocardial infarction, its minor elevations are also observed in other clinical situations, and the prognostic factors in such clinical settings have not been well established. The aim of this study was to identify predictors of mortality in patients with minor troponin elevations without an acute myocardial infarction. METHODS: We consecutively enrolled 134 patients from the emergency department with a peak troponin I level greater than the lower limit of detectability (0.04 ng/ml) but less than the 10% coefficient of variation cutoff value for diagnosis of myocardial infarction (0.26 ng/ml). These patients had chest pain or nonspecific symptoms of a circulatory abnormality but lacked the traditional features of an acute myocardial infarction. End point was defined as death from all causes. Cox regression analysis was used to test relations between clinical and biochemical variables and the outcome. RESULTS: During the follow-up of 7.6+/-7.4 months, 12 patients died. Age, log creatine kinase myocardial isoform, and log C-reactive protein were found to be significantly correlated with death. After adjusting for possible confounders in the multivariate model, age (hazard ratio 1.09, confidence interval 1.02-1.16, P=0.012), log creatine kinase myocardial isoform (hazard ratio 13.11, confidence interval 2.01-85.52, P=0.007), and log C-reactive protein (hazard ratio 1.64, confidence interval 1.02-2.56, P=0.041) were identified as independent predictors of mortality. CONCLUSIONS: Creatine kinase myocardial isoform and C-reactive protein levels and age can be integrated to risk-stratify patients with minor troponin I elevation for reasons other than acute myocardial infarction.


Assuntos
Infarto do Miocárdio/sangue , Infarto do Miocárdio/diagnóstico , Troponina I/sangue , Adulto , Idoso , Idoso de 80 Anos ou mais , Análise de Variância , Biomarcadores/sangue , Proteína C-Reativa/metabolismo , Doença da Artéria Coronariana/sangue , Creatina Quinase Forma MB/sangue , Feminino , Seguimentos , Humanos , Mediadores da Inflamação/sangue , Coreia (Geográfico) , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio/mortalidade , Valor Preditivo dos Testes , Prognóstico , Modelos de Riscos Proporcionais , Projetos de Pesquisa , Fatores de Risco , Análise de Sobrevida
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...